MiniMed 740G Insulin Pump (O.U.S. Version)
Class I - DangerousWhat Should You Do?
- Check if you have this product: Product Number/CFN (O.U.S. Version) MiniMed" 740G pump (MMT-1811, MMT-1812, MMT-1861, MMT-1862) UDI Codes: Pending Serial Numbers (O.U.S.): NG2644996H NG2645006H NG2645007H NG2645013H NG2645014H NG2645023H NG2645025H NG2645026H NG2645030H NG2645032H NG2645051H NG2645062H NG2645065H NG2645066H NG2645067H NG2645074H NG2645077H NG2645081H NG2645086H NG2645097H NG2645100H NG2645101H NG2645115H NG2645116H NG2645117H NG2645119H NG2645120H NG2645122H NG2645125H NG2645127H NG2645128H NG2645139H NG2645143H NG2645146H NG2645148H NG2645150H NG2645151H NG2645164H NG2645178H NG2645213H
- Do not eat it: Even if it looks and smells fine, do not consume this product.
- Throw it away or return it: You can return the product to the store for a full refund.
- Seek medical attention if needed: If you've consumed this product and feel unwell, contact your doctor immediately.
- Report problems: Report any issues to the FDA's Safety Reporting Portal.
⚠️ Emergency: If you experience severe symptoms after consuming this product, call 911 or Poison Control at 1-800-222-1222.
Recall Details
- Company:
- Medtronic MiniMed
- Reason for Recall:
- Due to battery cap deterioration, this may potentially result in an incomplete battery circuit (similar to when battery cap is not attached) and a loss of power/functionality of the insulin infusion pumps.
- Classification:
- Class I - Dangerous
Dangerous or defective products that predictably could cause serious health problems or death.
- Status:
- ongoing
Product Information
Full Description:
MiniMed 740G Insulin Pump (O.U.S. Version)
Product Codes/Lot Numbers:
Product Number/CFN (O.U.S. Version) MiniMed" 740G pump (MMT-1811, MMT-1812, MMT-1861, MMT-1862) UDI Codes: Pending Serial Numbers (O.U.S.): NG2644996H NG2645006H NG2645007H NG2645013H NG2645014H NG2645023H NG2645025H NG2645026H NG2645030H NG2645032H NG2645051H NG2645062H NG2645065H NG2645066H NG2645067H NG2645074H NG2645077H NG2645081H NG2645086H NG2645097H NG2645100H NG2645101H NG2645115H NG2645116H NG2645117H NG2645119H NG2645120H NG2645122H NG2645125H NG2645127H NG2645128H NG2645139H NG2645143H NG2645146H NG2645148H NG2645150H NG2645151H NG2645164H NG2645178H NG2645213H
Distribution:
Nationwide distribution
Official Source
Always verify recall information with the official FDA source:
View on FDA.govFDA Recall Number: Z-1357-2022
Related Recalls
All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
Paradigm REAL-Time Insulin Pump (MMT-522, MMT-722)
Medtronic MiniMed
All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
Paradigm REAL-Time Veo Insulin Pump (MMT-554, MMT-754)
Medtronic MiniMed
All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.